MYC rearrangements relate to significantly inferior 5-year progression-free survival (PFS) and OS after R-CHOP treatment in patients with DLBCL [78], and are more common in diagnosis samples of primary treatment failure patients (31%) [79], although this overrepresentation is not observed in R/R DLBCL patient samples (17%) [61]. Here, MYC is linked to diffuse large B-cell lymphoma.